Biotech boards burdened: Bridging the success gap
Biotech Voices is a collection of exclusive opinion editorials from some of the leading voices in biopharma on the biggest industry questions today. Think you have a voice that should be heard? Reach out to Amber Tong.
Based on our numerous conversations with board members and CEOs, we surmise that biotech boards are facing busy meeting agendas with a multitude of topics ranging from governance, financial audits, and budget reviews to compensation and board nomination work. While it is the job of the CEO to outline strategy and plans for the business, the board is tasked with pressure testing those proposals to ensure that they are sound. Often boards do not have ample time to review materials in advance, there is inadequate time for discussion or proper debate during the meeting, and members lend their support without having all the information in real time to assess underlying assumptions.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.